Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset
Executive Summary
AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.
You may also be interested in...
Five Topics That Shaped Japan Pharma In 2019
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
Need a specific report? 1000+ reports available
Buy Reports